- Report
- February 2024
- 120 Pages
Global
From €4255EUR$4,750USD£3,627GBP
- Report
- October 2023
- 150 Pages
Global
From €2911EUR$3,250USD£2,481GBP
€4344EUR$4,850USD£3,703GBP
- Report
- May 2024
- 200 Pages
Global
From €3717EUR$4,150USD£3,169GBP
- Report
- April 2024
- 140 Pages
Global
From €4433EUR$4,949USD£3,779GBP
- Report
- May 2023
- 182 Pages
Global
From €3224EUR$3,600USD£2,749GBP
- Report
- November 2022
- 288 Pages
Global
From €3224EUR$3,600USD£2,749GBP
- Report
- February 2024
- 98 Pages
Global
From €3500EUR$4,186USD£3,088GBP
- Report
- January 2024
- 91 Pages
Global
From €3500EUR$4,186USD£3,088GBP
The Syndromic Multiplex Diagnostic market is a subset of the Diagnostics industry that focuses on the development and commercialization of multiplex assays. These assays are used to detect multiple biomarkers from a single sample, allowing for the simultaneous diagnosis of multiple diseases or conditions. Multiplex assays are used in a variety of clinical settings, including infectious disease, oncology, and autoimmune disease.
The Syndromic Multiplex Diagnostic market is driven by the increasing demand for rapid and accurate diagnosis of multiple diseases. This demand is driven by the need for improved patient outcomes, cost savings, and the ability to diagnose multiple diseases in a single test.
Some companies in the Syndromic Multiplex Diagnostic market include Abbott, Bio-Rad, Cepheid, Luminex, and Qiagen. Show Less Read more